雷替曲塞不良反应特点的分析与评价

doi:10.3969/j.issn.1000-8535.2017.05.013

摘要/Abstract

摘要： 目的分析雷替曲塞致药品不良反应(ADR)的特点及相关因素影响,为临床用药提供参考依据。方法以“雷替曲塞”、“不良反应”、“raltitrexed”等为检索词,在中国期刊网全文数据库(CNKI)、维普中文期刊数据库等检索近5年的文献,共纳入符合标准文献28篇进行整理,分析雷替曲塞所致ADR类型及在不同给药剂量、联合化疗或同步放疗及老年患者、特殊给药途径下ADR发生的特点。结果雷替曲塞常见的ADR包括消化系统症状、中性粒细胞减少和转氨酶升高,而中性粒细胞减少和转氨酶升高对临床治疗影响较大。给药剂量对ADR影响较小,而联合放疗会增加骨髓抑制的风险;在两药联合化疗时,雷替曲塞与长春瑞滨联合致中性粒细胞减少的风险增加;雷替曲塞引起的转氨酶升高多为Ⅰ~Ⅱ级,高龄(≥70 a)、肝转移对转氨酶升高影响不大。结论雷替曲塞在不同治疗方案中的ADR发生存在差异,临床应用时应注意监测,防范严重和罕见ADR的发生。

关键词: 雷替曲塞, 不良反应, 联合用药, 中性粒细胞减少, 转氨酶升高

Abstract: Objective To Summarize the literature on adverse drug reactions(ADR) of Raltitrexed,in order to provide reference for the rational use of the drug in clinic. Methods Raltitrexed and adverse reaction were both used as key words to retrieve articles in CNKI and VIP database, 28literatures which met the inclusion and exclusion criteria were collected and analyzed. The characteristics of ADR were analyzed indifferent dosage, combined chemotherapy or radiotherapy, elderly patients and using with special administration. Results The main adverse reactions of Raltitrexed in the treatment included digestive system symptoms, neutropenia and elevation of aminotransferase, and the latter two had a great influence on the clinical treatment.Combination with radiotherapy increased the risk of myelosuppression. Incidence of neutropenia in combination Raltitrexed with Vinorelbine was higher. Transaminase elevations were generally Ⅰ-Ⅱ grades. Age(≥70 a) and liver metastasis had little effected on transaminase increase. Conclusion There were differences in the occurrence of ADR in different therapeutic schemes. Attention should be paid to ADRs of Raltitrexed especially to monitoring and reporting rare and severe ADRs in clinic.

Key words: Raltitrexed, ADRs, Combined medication, Neutropenia, Transaminase increased

杨微, 张文周, 林晓贞, 张霓. 雷替曲塞不良反应特点的分析与评价[J]. 广州医药, 2017, 48(5): 50-53.

YANG Wei, ZHANG Wenzhou, LIN Xiaozhen, ZHANG Ni. Analysis of literature on characteristics of adverse drug reactions of Raltitrexed[J]. Guangzhou Medical Journal, 2017, 48(5): 50-53.

参考文献

[1] 曹云娣,严文跃,刘宝瑞,等.雷替曲塞的研究进展及临床应用[J]. 临床医学研究与实践,2016,1(11):178-180.
[2] 杨建伟,林锦源,高炜,等.雷替曲塞/贝伐珠单抗联合伊立替康或奥沙利铂方案治疗晚期结直肠癌的临床观察[J]. 临床肿瘤学杂志,2013,18(1):70-73.
[3] 夏铀铀,王磊,宋大安,等.放疗联合雷替曲塞奥沙利铂同步治疗中晚期食管癌的Ⅱ期临床研究[J]. 中国肿瘤临床,2014,41(11):716-719.
[4] 王俊斌,吴穷,邹维艳,等.雷替曲塞或氟尿嘧啶联合伊立替康二线治疗晚期结直肠癌疗效分析[J]. 肿瘤防治研究,2014,41(12):1335-1338.
[5] 霍丹,张小丽,马玉芳,等.雷替曲塞联合多西他赛治疗晚期胃癌的临床研究[J]. 中国现代医药杂志,2011,13(10):27-29.
[6] 谢达成,李宁,王静珏,等.雷替曲塞联合伊立替康2周方案对比FOLFIRI方案二线治疗晚期结直肠癌的疗效观察[J]. 临床肿瘤学杂志,2013,18(2):140-143.
[7] 刘文稚,李孟考,陈祥明.雷替曲塞联合奥沙利铂治疗结直肠癌肝转移的临床研究[J]. 中华临床医师杂志(电子版),2015,9(1):146-148.
[8] 王佳蕾,李进,秦叔逵,等.雷替曲塞或氟尿嘧啶/亚叶酸钙联合奥沙利铂治疗局部晚期或复发转移性结直肠癌的随机对照多中心Ⅲ期临床试验[J]. 临床肿瘤学杂志,2012,17(1):6-11.
[9] 郭晶晶,郑勤,王立玮.雷替曲塞或氟尿嘧啶、亚叶酸钙联合奥沙利铂治疗转移性结直肠癌的疗效比较[J]. 实用癌症杂志,2013,28(5):518-520.
[10] 韩啸,张竞竞,王洪亚,等.雷替曲塞或氟尿嘧啶联合吉西他滨治疗晚期乳腺癌的疗效比较[J]. 蚌埠医学院学报,2013,38(8):946-950.
[11] 王亚丽,陈龙舟,李青国,等.雷替曲塞联合长春瑞滨治疗紫杉类耐药的老年复发转移乳腺癌的临床观察[J]. 肿瘤药学,2015,5(6):458-461.
[12] 庄志祥,沈旭东,沈丽琴,等.雷替曲塞与5-氟尿嘧啶联合奥沙利铂治疗晚期结直肠癌的疗效比较[J]. 苏州大学学报(医学版),2010,30(3):573-607.
[13] 张蓓.雷替曲塞与卡培他滨联合奥沙利铂治疗老年晚期结直肠癌的疗效比较[J]. 实用临床医药杂志,2012,16(19):99-101.
[14] 应怀昌,叶舟.雷替曲塞在晚期结直肠癌中的应用研究进展[J]. 现代肿瘤医学,2012,20(6):1318-1320.
[15] 唐杰,朱晓黎,沈建,等.雷替曲塞介入治疗中晚期原发性肝癌的疗效及安全性分析[J]. 临床肿瘤学杂志,2015,20(3):249-252.
[16] FERRERO J M, CHAMOREY E, MAGNE N, et al. The raltitrexed-vinorelbine combination:a phase I pharmacokinetic and pharmacodynamic trial in advanced Breast cancer[J]. Cancer Chemother Pharmacol,2002,50(6):459-464.
[17] MASSACESI C, SANTINI D, ROCCHI M B, et al. Raltitrexed-induced hepatotoxicity:multivariate analysis of predictive factors[J]. Anticancer Drugs,2003, 14(7):533-541.